Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

Inclusion Criteria

• •1. Metastatic gastroenteropancreatic NET with lymph nodes or liver metastases only.
• •2. WHO Grade 1 or 2, Ki 67 ≤ 20% (to be confirmed at Stanford)
• •3. Must be a candidate for cytoreductive surgery with the goal of R1 resection as determined by a multidisciplinary tumor board discussion
• •4. Measurable disease as determined by RECIST v1.1
• •5. Confirmed presence of somatostatin receptors on all target lesions as determined by 68Ga DOTA TATE PET scan
• •6. Patients ≥ 18 years of age.
• •7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1
• •8. Appropriate hematologic, liver and kidney function
• •9. Patients on octreotide long-acting release (LAR) at a fixed dose of 20 mg or 30 mg at 3 to 4 weeks intervals for at least 12 weeks prior to enrollment in the study